These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32946534)

  • 1. Binding of omeprazole to protein targets identified by monoclonal antibodies.
    Cartee NMP; Wang MM
    PLoS One; 2020; 15(9):e0239464. PubMed ID: 32946534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revealing the Mechanistic Pathway of Acid Activation of Proton Pump Inhibitors To Inhibit the Gastric Proton Pump: A DFT Study.
    Jana K; Bandyopadhyay T; Ganguly B
    J Phys Chem B; 2016 Dec; 120(51):13031-13038. PubMed ID: 27992223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of acid secretion following treatment with proton pump inhibitors.
    Shin JM; Sachs G
    Gastroenterology; 2002 Nov; 123(5):1588-97. PubMed ID: 12404233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The basis of differentiation of PPIs.
    Sachs G; Shin JM
    Drugs Today (Barc); 2004 Mar; 40 Suppl A():9-14. PubMed ID: 15190382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS; Berardi RR
    J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo.
    Shin JM; Homerin M; Domagala F; Ficheux H; Sachs G
    Biochem Pharmacol; 2006 Mar; 71(6):837-49. PubMed ID: 16405921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
    Besancon M; Simon A; Sachs G; Shin JM
    J Biol Chem; 1997 Sep; 272(36):22438-46. PubMed ID: 9278394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of cross-reactivity between proton pump inhibitors.
    Sobrevia Elfau MT; Garcés Sotillos M; Ferrer Clavería L; Segura Arazuri N; Monzón Ballarin S; Colás Sanz C
    J Investig Allergol Clin Immunol; 2010; 20(2):157-61. PubMed ID: 20461971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of proton pump inhibitors in children: a comprehensive review.
    Gibbons TE; Gold BD
    Paediatr Drugs; 2003; 5(1):25-40. PubMed ID: 12513104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.
    Robinson M; Horn J
    Drugs; 2003; 63(24):2739-54. PubMed ID: 14664653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lansoprazole inhibits the cysteine protease legumain by binding to the active site.
    Bosnjak T; Solberg R; Hemati PD; Jafari A; Kassem M; Johansen HT
    Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):89-99. PubMed ID: 30916878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reaction of proton pump inhibitors with model peptides results in novel products.
    Watson C; Zhu L; Guan S; Machen TE; Forte JG
    J Pharmacol Sci; 2013; 122(3):213-22. PubMed ID: 23877017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The physiological background behind and course of development of the first proton pump inhibitor.
    Lundell L
    Scand J Gastroenterol; 2015 Jun; 50(6):680-4. PubMed ID: 25857639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis or rupture: duration of acid inhibition by proton pump inhibitors.
    Sachs G; Shin JM; Pratha V; Hogan D
    Drugs Today (Barc); 2003 Mar; 39 Suppl A():11-4. PubMed ID: 12712216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulary management of proton pump inhibitors.
    Byrne MF; Murray FE
    Pharmacoeconomics; 1999 Sep; 16(3):225-46. PubMed ID: 10558037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
    Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
    Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different biochemical modes of action of two irreversible H+,K(+)-ATPase inhibitors, omeprazole and E3810.
    Morii M; Takeguchi N
    J Biol Chem; 1993 Oct; 268(29):21553-9. PubMed ID: 8408006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole.
    Johnson M; Guilford S; Libretto SE;
    Curr Med Res Opin; 2002; 18(5):303-10. PubMed ID: 12240793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The stereoselectivity of CYP2C19 on R- and S-isomers of proton pump inhibitors.
    Tian C; Zhu L; Yu D; Cao Z; Kang T; Zhu R
    Chem Biol Drug Des; 2014 May; 83(5):610-21. PubMed ID: 24350826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.